Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study

Andrea Tumminia a,*, Raffaella Romano b, Giuseppe Brugaletta b, Roberto Scicali b,c, Giuseppina Biondi d, Rosario Oliveri d, Marcello Romano b, Paola Magnano San Lio e

a Endocrinology, Department of Clinical and Experimental Medicine, Garibaldi-Nesima Hospital, 95122 Catania, Italy
b Geriatrics Unit, Garibaldi-Nesima Hospital, 95122 Catania, Italy
c Department of Clinical and Experimental Medicine, University of Catania, 95100 Catania, Italy
d Pneumology Unit, Garibaldi-Nesima Hospital, 95122 Catania, Italy
e Department of Clinical and Experimental Medicine, University of Catania, AOU Policlinico “G. Rodolico - San Marco”, 95123 Catania, Italy

Received 25 November 2021; received in revised form 11 March 2022; accepted 4 April 2022
Handling Editor: Dr L D'Erasmo
Available online 10 April 2022

KEYWORDS
Obesity; Dyslipidemia; COVID-19; SARS-CoV-2; Remdesivir

Abstract Background and aims: Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase was early identified as a promising therapeutic candidate against COVID-19. Our aim was to evaluate the impact of several metabolic parameters on Remdesivir effectiveness among hospitalized COVID-19 patients.

Methods and results: We conducted an observational study on patients with SARS-CoV-2-related pneumonia admitted between May 2020 and September 2021 to the COVID-19 Units of Internal Medicine, Pneumology and Intensive Care of Garibaldi Hospital, Catania, Italy, and treated with Remdesivir. The "Ordinal Scale For Clinical Improvement" was used to assess patients' clinical improvement within 28 days of hospitalization. Short-term mortality rate was also evaluated.

A total of 142 patients with SARS-CoV-2-related pneumonia were studied. The prevalence of obesity (20.7% vs. 41.9%, p = 0.03), the average BMI (27.1 ± 4.4 vs. 31.1 ± 6.1, p < 0.01) and the mean LDL-C levels (78 ± 19 mg/dl vs. 103 ± 18 mg/dl, p = 0.03) were significantly lower in early-improved (EI) compared to not-improved (NI) individuals. Obesity was negatively associated to clinical improvement after Remdesivir (OR 0.48, 95%CI 0.17–0.97, p = 0.04). Both obesity (OR 2.82, 95%CI 1.05–7.71, p = 0.04) and dyslipidemia (OR 2.78, 95%CI 1.17–7.16, p = 0.03) were significantly related to patients' mortality. Dyslipidemic subjects experienced a slower clinical improvement than non-dyslipidemic ones (Long-Rank p = 0.04).

Conclusion: Our study showed that unfavorable metabolic conditions such as obesity and dyslipidemia could predict a worse clinical response to Remdesivir as well as the mortality in hospitalized COVID-19 patients. Further prospective and larger-scale studies are needed to confirm these preliminary findings.

© 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

* Corresponding author. Fax: +39 095472988
E-mail address: andreatumminia82@gmail.com (A. Tumminia).

https://doi.org/10.1016/j.numecd.2022.04.005
0939-4753/© 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
1. Introduction

Since Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at the end of 2019 in China, it rapidly became a global pandemic [1]. Clinical manifestations of COVID-19 usually range from asymptomatic state or mild infection to severe forms of the disease that are life threatening [2]. This ongoing outbreak has pushed the researchers’ efforts to identify which clinical characteristics would have conferred to people an higher risk of getting infected, of developing critical illness and, ultimately, of dying from this disease [3]. On this regard, advanced age, male sex, the presence of chronic illness and/or multiple comorbidities (e.g. chronic lung diseases, cardiovascular diseases, obesity and diabetes mellitus) have been clearly identified as major risk factors for the development of severe COVID-19 [4–7]. Recent reports also indicated a role of dyslipidemia in severity and mortality from SARS-CoV-2 infection [8,9].

Several therapeutic agents have been investigated for clinical improvement and increasing survival of COVID-19 patients; some of them are anti-inflammatory drugs while the others including antivirals medications. Among antivirals, Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase was identified early as a promising therapeutic candidate for this disease [10–12]. Food and Drug Administration (FDA) approved the use of Remdesivir in severe hospitalized COVID-19 patients under an emergency use authorization on May 1st, 2020. Afterward, on August 28th, 2020, authorization of Remdesivir administration was expanded to non-severe COVID-19 patients. Finally, on October 22nd, 2020, Remdesivir became the first drug with the FDA approval for the treatment of COVID-19 [13]. In Italy, the Italian Medicine Agency (AIFA) approved Remdesivir in patients with COVID-19 pneumonia on oxygen therapy not requiring high-flow oxygen or mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and with symptom onset of less than 10 days.

Although the usefulness of this drug has been showed by several randomized controlled trials [10,12,14], there is still poor evidence regarding the clinical and biochemical predictors of Remdesivir effectiveness among patients hospitalized for SARS-CoV-2-related pneumonia.

Thus, the aim of the present study was to identify, in a real-world setting, any clinical condition and/or biochemical parameter able to predict an early clinical improvement (primary outcome) among Remdesivir-treated adult patients admitted to the hospital for SARS-CoV-2-related pneumonia.

2. Methods

We conducted a retrospective observational study on patients with SARS-CoV-2-related pneumonia, admitted between May 2020 and September 2021 to the COVID-19 Units of Internal Medicine, Pneumology and Intensive Care of Garibaldi Hospital, Catania, Italy. All the patients were treated with Remdesivir during the hospital stay.

The following baseline clinical, anthropometric and biochemical parameters were evaluated: body weight, height, body mass index (BMI, Kg/m²), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), glycated hemoglobin (HbA1c, determined by high-performance liquid chromatography), total cholesterol, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), calculated with Friedewald formula if triglycerides value was lower than 400 mg/dl [15]), triglycerides (TG), creatinine levels, estimated glomerular filtration rate (according to the Chronic Kidney Disease Epidemiology Collaboration formula [16]), glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), amylase, lipase, C-reactive protein (CRP), procalcitonin (PCT) and PaO₂/FiO₂ ratio.

The presence of different comorbidities was recorded and correlated to the clinical response to Remdesivir: hypertension (SBP ≥140 mmHg and/or DBP ≥ 90 mmHg, or taking antihypertensive medication), established cardiovascular diseases (myocardial infarction, heart failure, stroke), renal failure (eGFR <60 ml/min), diabetes mellitus (either anaemic or newly diagnosed during the hospital stay), obesity (BMI ≥30 kg/m²), dyslipidemia (defined according to the 2019 ESC/EAS guidelines cutoff values [17] or by already taking lipid-lowering drugs at the time of hospital admission), malignancies and chronic obstructive pulmonary diseases (COPD). Patients’ smoking habit and concomitant medications were also recorded.

The previously validated “Ordinal Scale For Clinical Improvement” (OSCI) [12] was used to assess patients’ early clinical improvement after Remdesivir (primary outcome), which was defined as the achievement of categories 1–3 on the scale and/or a 2-point reduction of the score (regardless of the starting level) within 28 days of hospitalization. The categories were as follows: 1, not hospitalized and no limitations of activities; 2, not hospitalized, with limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (related to COVID-19 or to other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or ECMO; and 8, death.

Patients were then defined as either early improved (EI) or not-improved (NI) on the basis of clinical achievements of the aforementioned criteria.

Secondary outcomes were the time to recovery, defined as the first day, during the 28 days after the first dose of Remdesivir, on which the patient met the aforementioned criteria, and the short-term (within one month since hospital admission) mortality rate.

The study was conducted in compliance with the principles of the Declaration of Helsinki and its later amendments [18] and was approved by the local ethics committee.
3. Sample size and statistical analysis

We estimated that a sample size of 140 patients would have given at least 85% power to detect a difference of 30% in reaching the primary outcome (early clinical improvement after Remdesivir), with an alpha of 0.05. The effect size estimation was based on the ratio of the percentage of patients obtaining the primary outcome (63.7%) in the control group and the expected percentage of early responders in the intervention group. The effect size was 0.25. The sample size estimation was based on the rate ratio for recovery (1.29) of the main randomized controlled trial on Remdesivir efficacy, the Adaptive COVID-19 Treatment Trial (ACTT-1) [12].

Shapiro–Wilk and Kolmogorov–Smirnov tests were used to determine whether the distribution of the continuous variables was normal. Graph analyses of histograms, Q–Q normality graph and asymmetry/standard error or kurtosis/standard error ratio were used to assess the distribution of continuous variables. Student’s t test or Mann–Whitney test were used when appropriate for continuous variables. A two-sided p value < 0.05 was considered statistically significant.

A multivariate logistic regression model corrected by age, gender, smoking habit, available markers of inflammation (CRP, PCT) and concomitant therapy with Baricitinib, a Janus kinase (JAK) inhibitor, was used to quantify the odds ratios (OR) with 95% confidence interval (CI) for the primary outcome occurrence on the basis of the different comorbidities. Hosmer–Lemeshow post-estimation test was used to assess the model performance.

An exploratory analysis of the distribution of continuous variables was performed using the graphic analyses of histogram, Q–Q normality graph and asymmetry/standard error or kurtosis/standard error ratio. The data were expressed as mean ± SD; if the data were not normal distributed, the median (IQR) was used. For categorical variables, the frequency (n, %) is shown.

A linear correlation between BMI values and the number of days needed for clinical improvement was also found in obese vs. non-obese (5.2 ± 2.0 days vs. 4.8 ± 1.8 days, respectively, p = 0.42) individuals. Moreover, average PaO₂/FiO₂ ratio at the time of first Remdesivir administration was similar in dyslipidemic vs. non-dyslipidemic (305.6 ± 107.9 vs. 321.1 ± 100.1, respectively, p = 0.49) and in obese vs. non-obese (315.2 ± 99.5 vs. 301.6 ± 97.5, respectively, p = 0.53) patients.

Among other comorbidities, obesity was negatively associated to clinical improvement after Remdesivir (OR 0.48, 95%CI 0.17–0.97, p = 0.04) (Table 3). Furthermore, both obesity (OR 2.82, 95% CI 1.05–7.21, p = 0.04) and dyslipidemia (OR 2.78, 95%CI 1.17–7.16, p = 0.03) were significantly related to early patient mortality (Table 4).

All the studied individuals underwent steroid therapy during hospitalization, while a similar percentage of patients in the two study groups was also treated with Baricitinib: 28.8% (32/111) vs. 25.8% (8/31) in EI vs. NI patients, respectively (p = 0.74).

Since Remdesivir response could be affected by the precocity of drug administration and by the patients’ clinical status (in terms of respiratory performance) at the time of prescription [19], we assessed these parameters in our cohort according to both dyslipidemia and obesity status. Notably, the mean time for Remdesivir prescription (from the onset of symptoms) was not different in dyslipidemic vs. non-dyslipidemic (4.9 ± 1.5 days vs. 4.7 ± 1.9 days, respectively, p = 0.72) as well as in obese vs. non-obese (5.2 ± 2.0 days vs. 4.8 ± 1.8 days, respectively, p = 0.42) individuals. Moreover, average PaO₂/FiO₂ ratio at the time of first Remdesivir administration was similar in dyslipidemic vs. non-dyslipidemic (305.6 ± 107.9 vs. 321.1 ± 100.1, respectively, p = 0.49) and in obese vs. non-obese (315.2 ± 99.5 vs. 301.6 ± 97.5, respectively, p = 0.53) patients.

A linear correlation between BMI values and the number of days needed for clinical improvement was also found (Fig. 1). Thus, the higher was BMI in our cohort, the longer was the time needed for the patient to recover. Finally, dyslipidemic subjects experienced a slower clinical improvement than non-dyslipidemic ones (Long-rank p = 0.04) (Fig. 2). This clinical pattern was not evident among obese patients (Long-Rank p = 0.25) (Fig. 3).

No other statistically significant differences were found in our cohort.

| Table 1 Baseline anamnestic and clinical characteristics of the studied population. |
|---------------------------------|-------------------|
| Patients’ baseline characteristics (n = 142) | |
| Age (years) | 66.0 ± 13.5 |
| Males (n, %) | 88 (61.9) |
| Smokers (n, %) | 23 (16.2) |
| Obesity (n, %) | 36 (25.3) |
| DM (n, %) | 46 (32.4) |
| Hypertension (n, %) | 97 (68.3) |
| Dyslipidemia (n, %) | 37 (26.1) |
| ECD (n, %) | 42 (29.6) |
| COPD (n, %) | 18 (12.7) |
| Renal failure (n, %) | 20 (14.1) |
| Malignancies (n, %) | 15 (10.6) |

Data are presented as means ± standard deviations (SD) for continuous variables or numbers and percentages (%) for categorical variables.

Abbreviations: DM, diabetes mellitus; ECD, established cardiovascular disease; COPD, chronic obstructive pulmonary diseases.
Table 2 Clinical, anthropometrical and biochemical characteristics of post-Remdesivir early improved (EI) vs. not improved (NI) individuals at baseline.

| Patients' characteristics | EI (n = 111) | NI (n = 31) | p     |
|--------------------------|-------------|-------------|-------|
| Demographic and anthropometrical |             |             |       |
| Age (years)              | 63.7 ± 13.0 | 74.3 ± 12.2 | <0.01 |
| Males (n, %)             | 71 (64.0)   | 17 (54.8)   | 0.35  |
| BMI (Kg/m²)              | 27.1 ± 4.4  | 31.1 ± 6.1  | <0.01 |
| Smokers (n, %)           | 16 (14.4)   | 7 (22.5)    | 0.31  |
| Comorbidities            |             |             |       |
| Obesity (n, %)           | 23 (20.7)   | 13 (41.9)   | 0.03  |
| Hypertension (n, %)      | 74 (66.7)   | 23 (74.2)   | 0.43  |
| Dyslipidemia (n, %)      | 26 (23.4)   | 11 (35.5)   | 0.26  |
| DM (n, %)                | 33 (29.7)   | 13 (41.9)   | 0.19  |
| ECD (n, %)               | 32 (28.8)   | 10 (32.2)   | 0.73  |
| COPD (n, %)              | 12 (10.8)   | 6 (19.3)    | 0.21  |
| Malignancies (n, %)      | 11 (9.9)    | 4 (12.9)    | 0.43  |
| Renal failure (n, %)     | 14 (12.6)   | 6 (19.3)    | 0.34  |
| Clinical and biochemical parameters |             |             |       |
| FPG (mg/dl)              | 115 ± 21    | 119 ± 23    | 0.76  |
| HbA1c (%)                | 6.3 ± 0.9   | 6.6 ± 1.2   | 0.67  |
| Average SBP (mmHg)       | 135 ± 6.3   | 137 ± 8.3   | 0.56  |
| Average DBP (mmHg)       | 85 ± 3.6    | 82 ± 2.9    | 0.77  |
| Total Cholesterol (mg/dl) | 142 ± 38    | 173 ± 34    | 0.11  |
| HDL-C (mg/dl)            | 39 ± 13     | 42 ± 8      | 0.23  |
| LDL-C (mg/dl)            | 78 ± 19     | 103 ± 18    | 0.03  |
| Triglycerides (mg/dl)    | 122 ± 36    | 141 ± 33    | 0.29  |
| Creatinine (mg/dl)       | 1.2 ± 0.6   | 1.3 ± 0.5   | 0.56  |
| GPT (mg/dl)              | 35 ± 20     | 39 ± 25     | 0.40  |
| AMP (mg/dl)              | 36 ± 29     | 31 ± 19     | 0.30  |
| Amylase (U/I/l)          | 71 ± 35     | 71 ± 41     | 0.99  |
| Lipase (U/I/l)           | 42 ± 26     | 46 ± 45     | 0.80  |
| CRP (mg/l)               | 99 ± 48     | 126 ± 67    | 0.71  |
| PCT (ng/ml)              | 0.1 ± 0.3   | 0.1 ± 0.2   | 0.82  |
| PaO₂/FiO₂ ratio          | 310.6 ± 103.7 | 313.3 ± 95.9 | 0.68  |

Concomitant medications

| ARBs (n, %) | 25 (22.5) | 8 (25.8) | 0.70 |
| ACE-I (n, %) | 26 (23.4) | 8 (25.8) | 0.78 |
| Beta blockers (n, %) | 15 (13.5) | 5 (16.1) | 0.71 |
| CCB (n, %) | 17 (15.3) | 6 (19.3) | 0.59 |
| Aspirin (n, %) | 60 (54.0) | 17 (54.8) | 0.93 |
| Statins (n, %) | 20 (18.0) | 9 (29.0) | 0.18 |
| Ezetimibe (n, %) | 5 (4.5) | 2 (6.4) | 0.66 |
| Fibrates (n, %) | 4 (3.6) | 2 (6.4) | 0.49 |
| Insulin therapy (n, %) | 10 (9.0) | 6 (19.3) | 0.11 |
| Metformin (n, %) | 28 (25.2) | 7 (22.6) | 0.76 |

Data are presented as means ± standard deviations (SD) for continuous variables or numbers and percentages (%) for categorical variables.

Abbreviations: EI, early improved patients; NI, not improved patients; BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; ECD, established cardiovascular disease; COPD, chronic obstructive pulmonary diseases; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; CRP, C-reactive protein; PCT, procalcitonin; ARBs, angiotensin II receptor blockers; ACE-I, angiotensin-converting enzyme inhibitors; CCB, calcium channel blockers.

5. Discussion

This study showed, for the first time to our knowledge, that unfavorable metabolic conditions such as obesity and dyslipidemia could predict not only (as it is already known) the severity of clinical course and mortality among SARS-CoV-2-infected individuals, but also worse clinical outcomes following Remdesivir in patients who are hospitalized for moderate-to-severe disease. In our population, in fact, obesity was negatively associated to clinical improvement after the antiviral therapy and (together with dyslipidemia) positively related to patients’ mortality. Dyslipidemia affected also the rapidity of clinical response, being dyslipidemic subjects slower than non-dyslipidemic ones in improving their clinical condition.

Since COVID-19 developed and became a pandemic, it has been well established that the presence of several comorbidities such as obesity and dyslipidemia represent a risk factor of clinical severity for subjects affected by SARS-CoV-2 infection [8,20–25]. Even if the exact underlined mechanisms of these associations have not been uniquely established, it is believed that the main pathophysiological link between SARS-CoV-2 infection and the above-mentioned disorders resides in the aberrant immune response, which characterizes these morbid conditions [26]. COVID-19, in fact, usually encompasses three main phases. In phase 1, the virus binds with ACE2 receptor on alveolar macrophages and epithelial cells, triggering toll like receptor (TLR) mediated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling. This phenomenon reduces the early immune response and, ultimately, allows unchecked viral replication. Phase 2 is characterized by hypoxia and innate immunity mediated pneumocyte damage as well as capillary leak. Phase 3 is the so-called “cytokine storm”, which is characterized by an abnormal and dysregulated immune response causing multi-organ inflammation, worsening respiratory symptoms and determining hemodynamic instability [27].

In detail, the association between COVID-19-related poor prognosis and the obesity state can be explained by the implication of several biological and physiopathological reasons. Firstly, it has been demonstrated that obesity violates the well-balanced system of adipocytes and immune cells, with subsequent disturbance to the immune surveillance system [28]. Immune system cells and adipocytes exhibit, in fact, similarities in structure and functions such as the production of various mediators, which could exert their action both locally and systemically. In obesity, macronutrient excess stimulates adipocytes to release pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and CRP as well as pro-thrombotic mediators such as fibrinogen and D-dimer [29,30]. Conversely, the production of anti-inflammatory adipokines (e.g. adiponectin) is reduced, thus predisposing the individual to a pro-inflammatory and pro-thrombotic state and to oxidative stress [31,32]. Furthermore, it is known that obesity itself can be responsible for an impaired immune response and altered chemotaxis and macrophage differentiation with an overall negative impact on the efficiency of defenses against pathogens [33]. Secondly, the well-known association of obesity with reduced lung function, impaired respiratory physiology
who are overweight or obese at risk of severe illness and poor response to mechanical ventilation places people

The impact of obesity and dyslipidemia on remdesivir effectiveness 1639

consequences such as a cytokine storm [37]. Oxidized LDL-oxidation, and oxidized LDLs lead to several downstream consequences. Accumulated lipids, particularly LDLs, are subject to further complicate this condition of low-level inflammation (C-reactive protein, procalcitonin) and concomitant therapy with Baricitinib, which is an enzyme that has been identified as a receptor for the spike protein of SARS-CoV-2, may also play a role in the pathophysiology of the obesity-related COVID-19 severity [35,36].

On the other hand dyslipidemia itself (which is commonly but not always related to overweight/obesity) could further complicate this condition of low-level inflammatory exposure and aberrant immune response. Accumulated lipids, particularly LDLs, are subject to oxidation, and oxidized LDLs lead to several downstream consequences such as a cytokine storm [37]. Oxidized LDL-C is also a powerful stimulator that can activate endothelial cells and monocytes, so it can increase the expression of a variety of inflammatory proteins and receptors and induce endothelial cell apoptosis through the NF-κB and caspases signaling, thus increasing monocyte levels, platelet activation, and vascular smooth muscle cell migration [38].

Endothelial dysfunction could, indeed, have a central role in the association between dyslipidemia/obesity and worse prognosis among COVID-19 patients. Since COVID-19 is widely considered an endothelial disease [39,40] and both dyslipidemia and obesity are pre-existing conditions, which are known to induce endothelial dysfunction, it is likely that both of them (either addititionally or synergistically) may worsen the endothelial response to infection.

That said, it is important to underline that in our cohort the disease was identified and treated precociously (less than 10 days since symptoms onset) by means of Remdesivir together with standard anti-inflammatory therapy. Nevertheless, both obese and dyslipidemic individuals showed significantly worse outcomes in terms of clinical improvement, time to recovery and mortality. This phenomenon might have an important biological meaning. It is possible to hypothesize, in fact, that metabolic dysfunctions could have played a deeper role in the pathophysiology of COVID-19 progression than previously thought, not only by affecting the “cytokine storm phase” (and therefore determining a dysregulation of patients’ immune response), but also by interfering with the anti-replicative effect of an antiviral drug (e.g. Remdesivir) already from the first phases of the disease (that is before the cytokine storm occurrence). Our study suggests, therefore, that treating and preventing obesity and dyslipidemia during pandemic could have a central role not only by decreasing inflammation-related infection severity, but also by ameliorating patients’ response to antivirals during the very early stages of the disease. The latter consideration appears to be clinically crucial considering the importance of an early diagnosis and treatment on COVID-19-related outcomes.

This study has strengths and limitation. Among strengths both the real-world approach and the novelty of the topic should be mentioned. Main limitations are represented by the retrospective design of the study (whose conclusions need to be supported by further and adequately powered prospective clinical studies), by the lack of a control group of Remdesivir-untreated COVID-19 patients, which would have been critical to support our hypotheses, and by the lack of information on several inflammation mediators (e.g. IL-6, TNF-α, etc) and on the SARS-CoV-2 viral load. Another limitation regards the timing of lipid profile assessment. It is, in fact, known that circulating levels of total cholesterol and LDL-C are lowered during acute infections [41,42]. Since, in our study, dyslipidemia has been defined based on either concomitant therapy with lipid-lowering drugs or serum LDL-C levels at hospital admission, the detected percentage of dyslipidemic patients could have been underestimated.

Nevertheless, we believe that this paper offers useful insights regarding the impact of metabolic disorders on the prognosis of COVID-19 individuals in a specific clinical

| Patients’ comorbidities | OR     | p     |
|-------------------------|--------|-------|
| Obesity                 | 2.82 (1.05–7.71) | 0.04  |
| DM                      | 1.50 (0.55–3.91)  | 0.42  |
| Hypertension            | 1.30 (0.41–4.44)  | 0.65  |
| Dyslipidemia            | 2.78 (1.17–7.16)  | 0.03  |
| ECD                     | 0.85 (0.51–1.42)  | 0.50  |
| COPD                    | 1.05 (0.26–3.60)  | 0.89  |
| Renal failure           | 1.56 (0.50–5.29)  | 0.40  |
| Malignancies            | 1.10 (0.24–4.67)  | 0.88  |

A multivariate logistic regression model corrected by: age, gender, smoking habit, available markers of inflammation (C-reactive protein, procalcitonin) and concomitant therapy with Baricitinib, which was used to quantify the odds (OR) with 95% confidence interval (CI) for the primary outcome to occur on the basis of the presence of the different comorbidities. Abbreviations: DM, diabetes mellitus; ECD, established cardiovascular disease; COPD, chronic obstructive pulmonary diseases.
setting, which is represented by those hospitalized inpatients treated with Remdesivir. Further larger-scale prospective studies are, however, needed to confirm our preliminary findings and to identify any additional predictors of differential clinical response to Remdesivir in SARS-CoV-2-infected patients.

Author contributions

Conceptualization, Andrea Tumminia, Raffaella Romano, Giuseppe Brugaletta, Roberto Scicali, Giuseppina Biondi, Rosario Oliveri, Marcello Romano, Paola Magnano San Lio; Resources, Andrea Tumminia, Raffaella Romano, Giuseppe Brugaletta, Giuseppina Biondi, Rosario Oliveri; Original Draft Preparation, Andrea Tumminia, Roberto Scicali; Review and Editing, Andrea Tumminia, Marcello Romano, Paola Magnano San Lio.

Funding

This research received no external funding.

Declaration of competing interest

All the authors declare no conflict of interest in connection with submitted material.

Acknowledgements

The authors thank Dr. Andrea Domenico Ruffolo and Dr. Francesco Stroscio for their contribution on data curation and analysis.

References

[1] Epidemiology Working Group for Ncip Epidemic Response CCDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Lixuebingxue Zazhi 2020;41:145–51.
[2] Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.
[3] Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerg Med 2021;16:281–308.
[4] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[5] Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43:867–9.
[6] Mauvais-Jarvis F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. Diabetes 2020;69:1857–63.
[7] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323:1574–81.
[8] Liu Y, Pan Y, Yin Y, Chen W, Li X. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J 2021;18:157.
[9] Zhang K, Dong SS, Guo Y, Tang SH, Wu H, Yao S, et al. Causal associations between blood lipids and COVID-19 risk: a two-sample

Figure 1 Linear correlation between BMI values and the number of days needed for clinical improvement after Remdesivir.

Figure 2 Kaplan–Meier survival estimates and Long-rank test in dyslipidemic and non-dyslipidemic subjects in terms of time to clinical improvement.

Figure 3 Kaplan–Meier survival estimates and Long-rank test in obese and non-obese subjects in terms of time to clinical improvement.
The impact of obesity and dyslipidemia on remdesivir effectiveness

subjects with familial hypercholesterolemia: a single lipid-center real-world evaluation. J Clin Med 2021;10.

Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018;9:7204–18.

Khadke S, Ahmed N, Ahmed N, Ratts R, Raju S, Gallogly M, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virol J 2020;17:154.

Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic inflammation in patients with obesity. Int J Obes 2020;44:1790–2.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.

Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020. medRxiv: the preprint server for health sciences.

Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci: AMS 2017;12:851–63.

Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and obesity: dangerous liaisons. J Clin Med 2020;9.

Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic Syndrome on immunity. Adv Nutr 2016;7:66–75.

Parameswaran K, Todde DC, Soth M. Altered respiratory physiology in obesity. Can Respir J J Can Thorac Soc 2006;13:203–11.

Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev: an official journal of the International Association for the Study of Obesity 2020;21:e13034.

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.

Khajavi A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179–84.

Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091.

Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020. medRxiv: the preprint server for health sciences.

Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci: AMS 2017;12:851–63.